Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4% and cutting sample processing time by up to 78%

- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo. The DxU Iris Workcell is a fully automated system that streamlines urinalysis workflow and reduces manual reviews to 4%. The new workcell will be showcased in a live launch event held in the AACC Expo hall, booth 1523, and live streamed via LinkedIn on September 28, 2021 at 12 p.m. EDT 9 a.m. PDT .


A routine urinalysis is one the most frequently ordered tests, representing up to 30% of all samples received in the lab 3 . Many of these samples require a lab technician to perform a manual inspection, which causes workflow disruption and a substantial increase in workload. Whether it is confirming the analyzer's findings or identifying unique particle types, manual microscopic reviews are time-consuming and can take up to six times longer per sample than with an automated system 4 .

Automating the routine urinalysis workflow with the DxU Iris Workcell reduces sample subjectivity and variability, helping laboratories of all sizes standardize processes, drive faster turnaround time and deliver quality results.

"There is no doubt that the pandemic has intensified pressure on the clinical laboratory," said Dr. Peter Soltani , senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "In this pressurized environment, manual reviews are particularly onerous because they are labor-intensive, taking time and focus away from scientific work. We designed the DxU Iris Workcell to allow urinalysis operators to automatically classify sediment particles, minimizing the need for human intervention."

The DxU Iris Workcell pairs the DxU 850m Iris or DxU 840m Iris urine microscopy analyzer with the Arkray AUTION MAX™ 4030 urine chemistry analyzer to create a scalable, fully automated urinalysis solution. The workcell was developed with proprietary Digital Flow Morphology technology with Auto-Particle Recognition (APR) Software to enable laboratories to deliver standardized results using artificial intelligence (AI). This industry-leading technology isolates, identifies and characterizes urine particles to provide immediate, accurate and reproducible results verified directly on the screen.

"As a Med Tech, it's important for me that any new analyzer we bring into the lab makes the workflow better and is easy to use with minimal maintenance. The DxU Iris has several features that can help med techs work more efficiently. One such feature is that the user guide with the key reference information is on the main screen," said Jennifer Soria , a hematology section coordinator for a medical group in Florida . "I love the new Load and Unload station as it can hold multiples racks, allowing users to work in other areas of the lab while processing urine samples."

The DxU Iris Workcell is designed for high-volume laboratories and features:

  • An optional Load and Unload station that increases the capacity of racks for a total of 190 onboard samples
  • Intuitive software user interface to comfortably navigate the analyzer menu, access key reference information and simplify user training in a format aligned across multiple Beckman Coulter instruments including hematology, chemistry and immunoassay
  • Connectivity with Beckman Coulter's advanced informatics software solutions: PRO Service remote service tool, DxONE Command Central remote monitoring, and REMISOL Advance middleware

To learn more about Beckman Coulter's DxU Iris Workcell and other urinalysis solutions, visit the website at www.beckmancoulter.com/DxUIris .

Members of the media can access the online press kit for the DxU Iris Workcell, including videos, images, and other assets at www.beckmancoulter.com/DxUIris-Media .

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing and found in hospitals, reference laboratories, and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes, and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics, and unlocking hidden value through performance partnership. A subsidiary of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter, Inc. is headquartered in Brea, Calif. , and has more than 11,000 global associates working diligently to make the world a healthier place.

© 2021 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2021-9662

ARKRAY, the stylized logo, and the ARKRAY products mentioned herein are trademarks or registered trademarks of ARKRAY in the United States .

REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.

References:
1 Broadlawns Medical Center. (2019). Manual microscopy divided by on-screen microscopic verification report generated December 20, 2019 . A case study published by Beckman Coulter. https://media.beckmancoulter.com/-/media/diagnostics/products/urinalysis/docs/ua-broadlawns-case-study.pdf .
2 Beaufort Memorial Urinalysis Workflow Case Study, CS-52048.
3 Delanghe, J., & Speeckaert, M. (2014). Preanalytical requirements of urinalysis. Biochemia Medica, 24(1), 89–104. https://doi.org/10.11613/BM.2014.011
4 https://www.mlo-online.com/home/article/13004799/automated-urinalysis-in-the-clinical-lab [Accessed: August 2, 2021 ]

DxU Iris Workcell

DxU Iris Workcell

DxU Iris Workcell

Beckman Coulter logo. (PRNewsfoto/Beckman Coulter)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulters-new-urinalysis-solution-improves-laboratory-workflow-by-significantly-reducing-manual-reviews-to-41-and-cutting-sample-processing-time-by-up-to-782-301386105.html

SOURCE Beckman Coulter Diagnostics

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×